Investigating the role of ECT2 in pancreatic cancer progression.
ECT2 Isoform Switch in Pancreatic Cancer.
This study is looking at how different versions of a gene called ECT2 might influence the growth of pancreatic cancer, and it needs patients to help by sharing tissue samples or information to find ways to detect the cancer earlier and develop new treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project ID | NIH-11034788 on NIH RePORTER |
What this research studies
This research focuses on understanding how different forms of the ECT2 gene contribute to the development and progression of pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer. The study will analyze the expression of two specific ECT2 mRNA variants in both precancerous lesions and tumors. By examining how these variants affect cancer cell behavior and patient survival, the research aims to identify potential biomarkers for early detection and new therapeutic targets. Patients may be involved in providing tissue samples or data to help elucidate the role of ECT2 in their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma or those with precancerous pancreatic lesions.
Not a fit: Patients with other types of cancer or those without pancreatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for pancreatic cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Jacksonville, United States
- Mayo Clinic Jacksonville — Jacksonville, United States (Active)
Researchers
- Principal investigator: Justilien, Verline — Mayo Clinic Jacksonville
- Study coordinator: Justilien, Verline
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.